Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines

Aloysious Ssemaganda, Ashwini Kumar Giddam, Mehfuz Zaman, Mariusz Skwarczynski, Istvan Toth, Danielle I Stanisic, Michael F Good, Aloysious Ssemaganda, Ashwini Kumar Giddam, Mehfuz Zaman, Mariusz Skwarczynski, Istvan Toth, Danielle I Stanisic, Michael F Good

Abstract

In the development of vaccines, the ability to initiate both innate and subsequent adaptive immune responses need to be considered. Live attenuated vaccines achieve this naturally, while inactivated and sub-unit vaccines generally require additional help provided through delivery systems and/or adjuvants. Liposomes present an attractive adjuvant/delivery system for antigens. Here, we review the key aspects of immunity against Plasmodium parasites, liposome design considerations and their current application in the development of a malaria vaccine.

Trial registration: ClinicalTrials.gov NCT02905019.

Keywords: Plasmodium; adjuvant; immunity; liposomes; malaria; vaccine.

Figures

Figure 1
Figure 1
Major liposome physicochemical characteristics that can be modified to direct immune responses elicited following vaccination (9).

References

    1. Russell PF, Mohan BN. The immunisation of fowls against mosquito-borne Plasmodium Gallinaceum by injections of serum and of inactivated homologous sporozoites. J Exp Med. (1942) 76:477–95. 10.1084/jem.76.5.477
    1. Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci. (2011) 366:2806–14. 10.1098/rstb.2011.0091
    1. Freund J, Sommer HE, Walter AW. Immunisation against malaria: vaccination of ducks with killed parasites incorporated with adjuvants. Science (1945) 102:200–2. 10.1126/science.102.2643.200
    1. Freund J, Thomson KJ, Sommer HE, Walter AW, Schenkein EL. Immunisation of rhesus monkeys against malarial infection (P. knowlesi) with killed parasites and adjuvants. Science (1945) 102:202–4. 10.1126/science.102.2643.202
    1. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature (1967) 216:160–2. 10.1038/216160a0
    1. Kaslow DC, Biernaux S. RTS,S: toward a first landmark on the malaria vaccine technology roadmap. Vaccine (2015) 33:7425–32. 10.1016/j.vaccine.2015.09.061
    1. World Health Organization. Malaria vaccine: WHO position paper, January 2016-Recommendations. Vaccine (2018) 36:3576–7. 10.1016/j.vaccine.2016.10.047
    1. Malaria Vaccine Funders Group (2013). Malaria Vaccine Technology Roadmap.
    1. Perrie Y, Crofts F, Devitt A, Griffiths HR, Kastner E, Nadella V. Designing liposomal adjuvants for the next generation of vaccines. Adv Drug Deliv Rev (2016) 99(Pt A):85–96. 10.1016/j.addr.2015.11.005
    1. Brito LA, O'Hagan DT. Designing and building the next generation of improved vaccine adjuvants. J Control Release (2014) 190:563–79. 10.1016/j.jconrel.2014.06.027
    1. Nevagi RJ, Toth I, Skwarczynski M. Peptide-based vaccines. In: Koutsopoulos S, editor. Peptide Applications in Biomedicine, Biotechnology and Bioengineering. Oxford: Elsevier Inc; (2018). p. 327–58.
    1. Baylor NW, Egan W, Richman P. Aluminum salts in vaccines–US perspective. Vaccine (2002) 20 (Suppl. 3):S18#x02013;23. 10.1016/S0264-410X(02)00166-4
    1. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine (2012) 30:4341–8. 10.1016/j.vaccine.2011.09.061
    1. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther. (2010) 10:639–51. 10.1517/14712591003724662
    1. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. . Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. (2015) 372:2087–96. 10.1056/NEJMoa1501184
    1. RTSS Clinical Trials Partnership (2015). Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386:31–45. 10.1016/S0140-6736(15)60721-8
    1. Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev Vaccines (2011) 10:589–99. 10.1586/erv.11.57
    1. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. . AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE (2012) 7:e33536. 10.1371/journal.pone.0033536
    1. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. . Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine (2011) 29:2461–73. 10.1016/j.vaccine.2011.01.011
    1. Kundi M, Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines (2007) 6:133–40. 10.1586/14760584.6.2.133
    1. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. . Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet (2007) 369:2161–70. 10.1016/S0140-6736(07)60946-5
    1. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines (2007) 6:723–39. 10.1586/14760584.6.5.723
    1. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. (2010) 12:17–23.
    1. Bovier PA. Recent advances with a virosomal hepatitis A vaccine. Expert Opin Biol Ther. (2008) 8:1177–85. 10.1517/14712598.8.8.1177
    1. Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine (2002) 20 (Suppl. 5):B17–23 10.1016/S0264-410X(02)00512-1
    1. Román VR, Jensen KJ, Jensen SS, Leo-Hansen C, Jespersen S, da Silva Te D, et al. . Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau. AIDS Res Hum Retroviruses (2013) 29:1504–12. 10.1089/AID.2013.0076
    1. van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine (2014) 32:7098–107. 10.1016/j.vaccine.2014.10.036
    1. Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, et al. . First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine (2015) 33:4130–40. 10.1016/j.vaccine.2015.06.051
    1. Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S, et al. . Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine (2017) 35:1652–61. 10.1016/j.vaccine.2017.01.055
    1. Hussein J, Zewdie M, Yamuah L, Bedru A, Abebe M, Dagnew AF, et al. . A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31(R) in people living in a TB-endemic area. Trials (2018) 19:24. 10.1186/s13063-017-2354-0
    1. Levine AS, Levy HB. Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep. (1978) 62:1907–12.
    1. Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, et al. . Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer (2010) 102:1129–36. 10.1038/sj.bjc.6605611
    1. Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines (2007) 6:761–72. 10.1586/14760584.6.5.761
    1. Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol. (2009) 87:371–6. 10.1038/icb.2009.21
    1. Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol. (2012) 61 (Pt 7):935–43. 10.1099/jmm.0.040857-0
    1. Behzad H, Huckriede AL, Haynes L, Gentleman B, Coyle K, Wilschut JC, et al. . GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis. (2012) 205:466–73. 10.1093/infdis/jir769
    1. McKenzie A, Watt M, Gittleson C. ISCOMATRIX() vaccines: safety in human clinical studies. Hum Vaccin (2010) 6:237–46. 10.4161/hv.6.3.10754
    1. Stratmann T. Cholera Toxin Subunit B as adjuvant–an accelerator in protective immunity and a break in autoimmunity. Vaccines (2015) 3:579–96. 10.3390/vaccines3030579
    1. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature (1974) 252:252. 10.1038/252252a0
    1. Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines (2014) 2:159–82. 10.1177/2051013614541440
    1. Marasini N, Ghaffar KA, Skwarczynski M, Toth I. Liposomes as a vaccine delivery system. In: Skwarczynski M, Toth I. editors. Micro and Nanotechnologies for Vaccine Development. Oxford, UK: Elsevier Inc; (2017). p. 221–39. 10.1016/B978-0-323-39981-4.00012-9
    1. Ghaffar KA, Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposomes as nanovaccine delivery systems. Curr Top Med Chem. (2014) 14:1194–208. 10.2174/1568026614666140329232757
    1. Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine (2012) 7:1877–93. 10.2217/nnm.12.157
    1. Tran TM, Li S, Doumbo S, Doumtabe D, Huang CY, Dia S, et al. . An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis. (2013) 57:40–7. 10.1093/cid/cit174
    1. Stanisic DI, Good MF. Examining cellular immune responses to inform development of a blood-stage malaria vaccine. Parasitology (2016) 143:208–23. 10.1017/S0031182015001092
    1. Fujioka H, Aikawa M. The malaria parasite and its life-cycle. In: editors Wahlgren M, Perlmann P. Malaria Molecular and Clinical Aspects. Amsterdam: Harwood Academic Publishers; (1999). p. 19–53.
    1. Chatterjee S, Wery M, Sharma P, Chauhan VS. A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Infect Immun. (1995) 63:4375–81.
    1. Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, et al. . TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites. Cell (1997) 90:511–22. 10.1016/S0092-8674(00)80511-5
    1. John CC, Zickafoose JS, Sumba PO, King CL, Kazura JW. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun. (2003) 71:4320–5. 10.1128/IAI.71.8.4320-4325.2003
    1. John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, et al. . Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg. (2005) 73:222–8. 10.4269/ajtmh.2005.73.222
    1. Offeddu V, Thathy V, Marsh K, Matuschewski K. Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. Int J Parasitol. (2012) 42:535–48. 10.1016/j.ijpara.2012.03.011
    1. Vanderberg JP, Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol. (2004) 34:991–6. 10.1016/j.ijpara.2004.05.005
    1. Sinnis P, Coppi A. A long and winding road: the Plasmodium sporozoite's journey in the mammalian host. Parasitol Int. (2007) 56:171–8. 10.1016/j.parint.2007.04.002
    1. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunisation with a nonreplicating sporozoite vaccine (PfSPZ). Science (2013) 341:1359–65. 10.1126/science.1241800
    1. Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. (2016) 22:614–23. 10.1038/nm.4110
    1. Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et al. . Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight (2017) 2:e89154. 10.1172/jci.insight.89154
    1. Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, et al. . Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA. (2017) 114:2711–6. 10.1073/pnas.1615324114
    1. Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. . Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. (2017) 17:498–509. 10.1016/S1473-3099(17)30104-4
    1. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS01 candidate vaccine. Hum Vaccine (2010) 6:90–6. 10.4161/hv.6.1.9677
    1. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. . First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. (2011) 365:1863–75. 10.1056/NEJMoa1102287
    1. Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, et al. . Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P. falciparum clinical malaria. PLoS ONE (2011) 6:e25786. 10.1371/journal.pone.0025786
    1. White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, et al. . Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. (2015) 15:1450–8. 10.1016/S1473-3099(15)00239-X
    1. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, et al. . A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. (2012) 367:2284–95. 10.1056/NEJMoa1208394
    1. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature (1987) 330:664–6. 10.1038/330664a0
    1. Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA. (1988) 85:573–6. 10.1073/pnas.85.2.573
    1. Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, et al. . Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J Exp Med. (1994) 180:353–8. 10.1084/jem.180.1.353
    1. Krzych U, Lyon JA, Jareed T, Schneider I, Hollingdale MR, Gordon DM, et al. . T-lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood-stage malaria antigens. J Immunol. (1995) 155:4072–7.
    1. Doolan DL, Hoffman SL. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol. (1999) 163:884–92.
    1. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan D, et al. Protection of humans against malaria by immunisation with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. (2002) 185:1155–64. 10.1086/339409
    1. Hollingdale MR, Krzych U. Immune responses to liver-stage parasites: implications for vaccine development. In: Perlmann P, Troye-Blomberg M. editors. Malaria Immunology. Basel: Karger; (2002). p. 27.
    1. Sinnis P, Nardin E. Sporozoite antigens: biology and immunology of the circumsporozoite protein and thrombospondin-related anonymous protein. In: Perlmann P, Troye-Blomberg M. editors. Malaria Immunology Basel: Karger; (2002). p. 26.
    1. Steers N, Schwenk R, Bacon DJ, Berenzon D, Williams J, Krzych U. The immune status of Kupffer cells profoundly influences their responses to infectious Plasmodium berghei sporozoites. Eur J Immunol. (2005) 35:2335–46. 10.1002/eji.200425680
    1. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. . Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. (2009) 361:468–77. 10.1056/NEJMoa0805832
    1. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. . Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet (2011) 377:1770–6. 10.1016/S0140-6736(11)60360-7
    1. Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, et al. Protection against malaria after immunisation by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA. (2013) 110:7862–7. 10.1073/pnas.1220360110
    1. Mordmüller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. . Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature (2017) 542:445–9. 10.1038/nature21060
    1. Behet MC, Foquetm L, van Gemert GJ, Bijker EM, Meuleman P, Leroux-Roels G. Sporozoite immunisation of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar J. (2014) 13:136. 10.1186/1475-2875-13-136
    1. Stevenson MM, Riley EM. Innate immunity to malaria. Nat Rev Immunol. (2004) 4:169–80. 10.1038/nri1311
    1. Crompton PD, Moebius J, Portugal S, Waisberg M, Hart G, Garver LS, et al. . Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. Annu Rev Immunol. (2014) 32:157–87. 10.1146/annurev-immunol-032713-120220
    1. Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, Akira S, et al. . Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem. (2005) 280:8606–16. 10.1074/jbc.M413541200
    1. Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, Visintin A, et al. . Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA. (2007) 104:1919–24. 10.1073/pnas.0608745104
    1. Shio MT, Eisenbarth SC, Savaria M, Vinet AF, Bellemare MJ, Harder KW, et al. . Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog. (2009) 5:e1000559. 10.1371/annotation/abca067d-b82b-4de6-93c5-0fcc38e3df05
    1. Sharma S, DeOliveira RB, Kalantari P, Parroche P, Goutagny N, Jiang Z, et al. . Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity (2011) 35:194–207. 10.1016/j.immuni.2011.05.016
    1. Ing R, Stevenson MM. Dendritic cell and NK cell reciprocal cross talk promotes gamma interferon-dependent immunity to blood-stage Plasmodium chabaudi AS infection in mice. Infect Immun. (2009) 77:770–82. 10.1128/IAI.00994-08
    1. Stevenson MM, Ing R, Berretta F, Miu J. Regulating the adaptive immune response to blood-stage malaria: role of dendritic cells and CD4(+)Foxp3(+) regulatory T cells. Int J Biol Sci. (2011) 7:1311–22. 10.7150/ijbs.7.1311
    1. Urban BC, Ing R, Stevenson MM. Early interactions between blood-stage Plasmodium parasites and the immune system. Curr Top Microbiol Immunol. (2005) 297:25–70. 10.1007/3-540-29967-X_2
    1. Hansen DS, D'Ombrain MC, Schofield L. The role of leukocytes bearing natural killer complex receptors and killer immunoglobulin-like receptors in the immunology of malaria. Curr Opin Immunol. (2007) 19:416–23. 10.1016/j.coi.2007.07.011
    1. Porcherie A, Mathieu C, Peronet R, Schneider E, Claver J, Commere PH, et al. . Critical role of the neutrophil-associated high-affinity receptor for IgE in the pathogenesis of experimental cerebral malaria. J Exp Med. (2011) 208:2225–36. 10.1084/jem.20110845
    1. Horowitz A, Newman KC, Evans JH, Korbel DS, Davis DM, Riley EM. Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. J Immunol. (2010) 184:6043–52. 10.4049/jimmunol.1000106
    1. Stanisic DI, Cutts J, Eriksson E, Fowkes FJ, Rosanas-Urgell A, Siba P, et al. . γδ T cells and CD14+ monocytes are predominant cellular sources of cytokines and chemokines associated with severe malaria. J Infect Dis. 210:295–305. (2014). 10.1093/infdis/jiu083
    1. Jagannathan P, Kim CC, Greenhouse B, Nankya F, Bowen K, Eccles-James I, et al. . Loss and dysfunction of Vdelta2(+) gammadelta T cells are associated with clinical tolerance to malaria. Sci Transl Med. (2014) 6:251ra117. 10.1126/scitranslmed.3009793
    1. Kurup SP, Harty JT. γδ T cells and immunity to human malaria in endemic regions. Ann Transl Med. (2015) 3(Suppl. 1):S22. 10.3978/j.issn.2305-5839.2015.02.22
    1. Cohen S, Mc Gregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature (1961) 192:733–7. 10.1038/192733a0
    1. McGregor IA, Carrington SP, Cohen S. Treatment of East African P. falciparum malaria with West African human γ-globulin. Trans R Soc Trop Med Hyg. (1963) 57:170–5. 10.1016/0035-9203(63)90058-0
    1. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, et al. . Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg. (1991) 45:297–308. 10.4269/ajtmh.1991.45.297
    1. Wåhlin B, Wahlgren M, Perlmann H, Berzins K, Björkman A, Patarroyo ME, et al. . Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibit merozoite invasion. Proc Natl Acad Sci USA. (1984) 81:7912–6.
    1. Udeinya IJ, Schmidt JA, Aikawa M, Miller LH, Green I. Falciparum malaria-infected erythrocytes specifically bind to cultured human endothelial cells. Science (1981) 213:555–7. 10.1126/science.7017935
    1. Treutiger CJ, Hedlund I, Helmby H, Carlson J, Jepson A, Twumasi P, et al. Rosette formation in Plasmodium falciparum isolates and anti-rosette activity of sera from Gambians with cerebral or uncomplicated malaria. Am J Trop Med Hyg. (1992) 46:503–10. 10.4269/ajtmh.1992.46.503
    1. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med. (1995) 182:409–18. 10.1084/jem.182.2.409
    1. Perlmann P, Troye-Blomberg M. Malaria and the immune system in humans. In: Perlmann P, Troye-Blomberg M. editors. Malaria Immunology. Basel: Kager; (2002). p. 229–242. 10.1159/000058846
    1. Süss G, Eichmann K, Kury E, Linke A, Langhorne J. Roles of CD4- and CD8-bearing T lymphocytes in the immune response to the erythrocytic stages of Plasmodium chabaudi. Infect Immun. (1988) 56:3081–8.
    1. Podoba JE, Stevenson MM. CD4+ and CD8+ T lymphocytes both contribute to acquired immunity to blood-stage Plasmodium chabaudi AS. Infect Immun. (1991) 59:51–8.
    1. Amante FH, Good MF. Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunol. (1997) 19:16. 10.1046/j.1365-3024.1997.d01-187.x
    1. Langhorne J, Gillard S, Simon B, Slade S, Eichmann K. Frequencies of CD4+ T cells reactive with Plasmodium chabaudi chabaudi: distinct response kinetics for cells with Th1 and Th2 characteristics during infection. Int Immunol. (1989) 1:416–24. 10.1093/intimm/1.4.416
    1. Langhorne J, Meding SJ, Eichmann K, Gillard SS. The response of CD4+ T cells to Plasmodium chabaudi chabaudi. Immunol Rev. (1989) 112:71–94. 10.1111/j.1600-065X.1989.tb00553.x
    1. Perez-Mazliah D, Langhorne J. CD4 T-cell subsets in malaria: TH1/TH2 revisited. Front Immunol. (2015) 5:671. 10.3389/fimmu.2014.00671
    1. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, et al. . Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet (2002) 360:610–7. 10.1016/S0140-6736(02)09784-2
    1. Edstein MD, Kotecka BM, Anderson KL, Pombo DJ, Kyle DE, Rieckmann KH, et al. . Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother. (2005) 49:4421–2. 10.1128/AAC.49.10.4421-4422.2005
    1. Robinson LJ, D'Ombrain MC, Stanisic DI, Taraika J, Bernard N, Richards JS, et al. . Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea. Infect Immun. (2009) 77:3033–43. 10.1128/IAI.00211-09
    1. Jagannathan P, Eccles-James I, Bowen K, Nankya F, Auma A, Wamala S, et al. . IFNγ/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children. PLoS Pathog. (2014) 10:e1003864. 10.1371/journal.ppat.1003864
    1. Boyle MJ, Jagannathan P, Bowen K, McIntyre TI, Vance HM, Farrington LA, et al. . Effector phenotype of Plasmodium falciparum-specific CD4(+) T cells is influenced by both age and transmission intensity in naturally exposed populations. J Infect Dis. (2015) 212:416–25. 10.1093/infdis/jiv054
    1. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, et al. . Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. (2000) 192:1545–52. 10.1084/jem.192.11.1545
    1. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med. (2000) 192:1553–62. 10.1084/jem.192.11.1553
    1. Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC. Subspecialization of CXCR5(+) T cells: B helper activity is focused in a germinal center-localized subset of CXCR5(+) T cells. J Exp Med. (2001) 193:1373–81. 10.1084/jem.193.12.1373
    1. Pérez-Mazliah D, Nguyen MP, Hosking C, McLaughlin S, Lewis MD, Tumwine I, et al. . Follicular helper T cells are essential for the elimination of Plasmodium infection. EBio Med. (2017) 24:216–30. 10.1016/j.ebiom.2017.08.030
    1. Stockinger B, Kassiotis G, Bourgeois C. Homeostasis and T cell regulation. Curr Opin Immunol. (2004) 16:775–9. 10.1016/j.coi.2004.09.003
    1. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. (2008) 9:239–44. 10.1038/ni1572
    1. Omer FM, Riley EM. Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J Exp Med. (1998) 188:39–48. 10.1084/jem.188.1.39
    1. Day NP, Hien TT, Schollaardt T, Loc PP, Chuong LV, Chau TT, et al. . The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis. (1999) 180:1288–97. 10.1086/315016
    1. Li C, Corraliza I, Langhorne J. A defect in interleukin-10 leads to enhanced malarial disease in Plasmodium chabaudi chabaudi infection in mice. Infect Immun. (1999) 67:4435–42.
    1. Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis. (2002) 185:971–9. 10.1086/339408
    1. Couper KN, Blount DG, Wilson MS, Hafalla JC, Belkaid Y, Kamanaka M, et al. . IL-10 from CD4CD25Foxp3CD127 adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PLoS Pathog. (2008) 4:e1000004. 10.1371/journal.ppat.1000004
    1. Scholzen A, Mittag D, Rogerson SJ, Cooke BM, Plebanski M. Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathog. (2009) 5:e1000543. 10.1371/journal.ppat.1000543
    1. Nie CQ, Bernard NJ, Schofield L, Hansen DS. CD4+ CD25+ regulatory T cells suppress CD4+ T-cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis. Infect Immun. (2007) 75:2275–82. 10.1128/IAI.01783-06
    1. Cambos M, Bélanger B, Jacques A, Roulet A, Scorza T. Natural regulatory (CD4+CD25+FOXP+) T cells control the production of pro-inflammatory cytokines during Plasmodium chabaudi adami infection and do not contribute to immune evasion. Int J Parasitol. (2008) 38:229–38. 10.1016/j.ijpara.2007.07.006
    1. Hisaeda H, Maekawa Y, Iwakawa D, Okada H, Himeno K, Kishihara K, et al. . Escape of malaria parasites from host immunity requires CD4+ CD25+ regulatory T cells. Nat Med. (2004) 10:29–30. 10.1038/nm975
    1. Amante FH, Stanley AC, Randall LM, Zhou Y, Haque A, McSweeney K, et al. . A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am J Pathol. (2007) 171:548–59. 10.2353/ajpath.2007.061033
    1. Finney OC, Riley EM, Walther M. Regulatory T cells in malaria - friend or foe? Trends Immunol. (2010) 31:63–70. 10.1016/j.it.2009.12.002
    1. Hansen DS, Schofield L. Natural regulatory T cells in malaria: host or parasite allies? PLoS Pathog (2010) 6:e1000771. 10.1371/journal.ppat.1000771
    1. Scholzen A, Minigo G, Plebanski M. Heroes or villains? T regulatory cells in malaria infection. Trends Parasitol. (2010) 26:16–25. 10.1016/j.pt.2009.10.004
    1. Walther M, Tongren JE, Andrews L, Korbel D, King E, Fletcher H, et al. . Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity (2005) 23:287–96. 10.1016/j.immuni.2005.08.006
    1. Jangpatarapongsa K, Chootong P, Sattabongkot J, Chotivanich K, Sirichaisinthop J, Tungpradabkul S, et al. . Plasmodium vivax parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells. Eur J Immunol. (2008) 38:2697–705. 10.1002/eji.200838186
    1. Minigo G, Woodberry T, Piera KA, Salwati E, Tjitra E, Kenangalem E, et al. . Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog. (2009) 5:e1000402. 10.1371/journal.ppat.1000402
    1. Bueno LL, Morais CG, Araújo FF, Gomes JA, Corrêa-Oliveira R, Soares IS, et al. . Plasmodium vivax: induction of CD4+CD25+FoxP3+ regulatory T cells during infection are directly associated with level of circulating parasites. PLoS ONE (2010) 5:e9623. 10.1371/journal.pone.0009623
    1. Panichakul T, Sattabongkot J, Chotivanich K, Sirichaisinthop J, Cui L, Udomsangpetch R. Production of erythropoietic cells in vitro for continuous culture of Plasmodium vivax. Int J Parasitol. (2007) 37:1551–7. 10.1016/j.ijpara.2007.05.009
    1. Tamez PA, Liu H, Fernandez-Pol S, Haldar K, Wickrema A. Stage-specific susceptibility of human erythroblasts to Plasmodium falciparum malaria infection. Blood (2009) 114:3652–5. 10.1182/blood-2009-07-231894
    1. Lundie RJ, de Koning-Ward TF, Davey GM, Nie CQ, Hansen DS, Lau LS, et al. . Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells. Proc Natl Acad Sci USA. (2008) 105:14509–14. 10.1073/pnas.0806727105
    1. Imai T, Ishida H, Suzue K, Hirai M, Taniguchi T, Okada H, et al. . CD8(+) T cell activation by murine erythroblasts infected with malaria parasites. Sci Rep. (2013) 3:1572. 10.1038/srep01572
    1. Imai T, Ishida H, Suzue K, Taniguchi T, Okada H, Shimokawa C, et al. . Cytotoxic activities of CD8(+) T cells collaborate with macrophages to protect against blood-stage murine malaria. Elife (2015) 4:e04232. 10.7554/eLife.04232
    1. Imai T, Shen J, Chou B, Duan X, Tu L, Tetsutani K, et al. . Involvement of CD8+ T cells in protective immunity against murine blood-stage infection with Plasmodium yoelii 17XL strain. Eur J Immunol. (2010) 40:1053–61. 10.1002/eji.200939525
    1. Horne-Debets JM, Faleiro R, Karunarathne DS, Liu XQ, Lineburg KE, Poh CM, et al. . PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. Cell Rep. (2013) 5:1204–13. 10.1016/j.celrep.2013.11.002
    1. Mazumdar T, Anam K, Ali N. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. J Parasitol. (2005) 91:269–74. 10.1645/GE-356R1
    1. van Houte AJ, Snippe H, Schmitz MG, Willers JM. Characterization of immunogenic properties of haptenated liposomal model membranes in mice. V Effect of membrane composition on humoral and cellular immunogenicity. Immunology (1981) 44:561–8.
    1. Bakouche O, Gerlier D. Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition. Immunology (1986) 58:507–13.
    1. Mannock DA, Lee MY, Lewis RN, McElhaney RN. Comparative calorimetric and spectroscopic studies of the effects of cholesterol and epicholesterol on the thermotropic phase behaviour of dipalmitoylphosphatidylcholine bilayer membranes. Biochim Biophys Acta (2008) 1778:2191–202. 10.1016/j.bbamem.2008.05.004
    1. Christensen D, Henriksen-Lacey M, Kamath AT, Lindenstrøm T, Korsholm KS, Christensen JP, et al. . A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J Control Release (2012) 160:468–76. 10.1016/j.jconrel,.2012.03.016
    1. Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, et al. . Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release (2010) 145:102–8. 10.1016/j.jconrel.2010.03.027
    1. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, Perrie Y, et al. . Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release (2010) 142:180–6. 10.1016/j.jconrel.2009.10.022
    1. Basile L, Passirani C, Huynh NT, Béjaud J, Benoit JP, Puglisi G, et al. . Serum-stable, long-circulating paclitaxel-loaded colloidal carriers decorated with a new amphiphilic PEG derivative. Int J Pharm. (2012) 426:231–8. 10.1016/j.ijpharm.2012.01.038
    1. Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm. (2002) 240:95–102. 10.1016/S0378-5173(02)00129-1
    1. Kaur R, Bramwell VW, Kirby DJ, Perrie Y. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control Release (2012) 158:72–7. 10.1016/j.jconrel.2011.10.012
    1. Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine (2009) 27:3643–9. 10.1016/j.vaccine.2009.03.040
    1. Brewer JM, Pollock KG, Tetley L, Russell DG. Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J Immunol (2004) 173:6143–50. 10.4049/jimmunol.173.10.6143
    1. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. (2008) 38:1404–13. 10.1002/eji.200737984
    1. Henriksen-Lacey M, Devitt A, Perrie Y. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release (2011) 154:131–7. 10.1016/j.jconrel.2011.05.019
    1. Ghaffar KA, Marasini N, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, et al. . The role of size in development of mucosal liposome-lipopeptide vaccine candidates against group A Streptococcus. Med Chem. (2016) 13:22–7. 10.2174/1573406412666160720093138
    1. Janeway CA. How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci USA. (2001) 98:7461–8. 10.1073/pnas.131202998
    1. Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J. (2010) 16:382–91. 10.1097/PPO.0b013e3181eaca65
    1. Tong NK, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al. . Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. (2005) 68:2298–303. 10.1111/j.1523-1755.2005.00689.x
    1. Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 2:97–105.
    1. Vyas SP, Goyal AK, Khatri K. Mannosylated liposomes for targeted vaccines delivery. Methods Mol Biol. (2010) 605:177–88. 10.1007/978-1-60327-360-2_12
    1. Marasini N, Giddam AK, Ghaffar KA, Batzloff MR, Good MF, Skwarczynski M, et al. . Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus. Nanomedicine (2016) 11:1223–36. 10.2217/nnm.16.36
    1. Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, et al. . Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release (2010) 147:342–9.
    1. Ballou WR, Rothbard J, Wirtz R, Gordon D, Williams J, Gore R, et al. . Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science (1985) 228:996–9. 10.1126/science.2988126
    1. Alving CR, Richards RL, Moss J, Alving LI, Clements JD, Shiba T, et al. . Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen. Vaccine (1986) 4:166–72. 10.1016/0264-410X(86)90005-8
    1. Richards RL, Hayre MD, Hockmeyer WT, Alving CR. Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect Immun. (1988) 56:682–6.
    1. Alving CR, Richards RL, Hayre MD, Hockmeyer WT, Wirtz RA. Liposomes as carriers of vaccines: development of a liposomal malaria vaccine. In: Gregoriadis G, Allison AC, Poste G, editors. Immunological Adjuvants and Vaccines. Boston, MA: Springer; (1989). p. 123–31. 10.1007/978-1-4757-0283-5_13
    1. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M, et al. . Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci USA. (1992) 89:358–62. 10.1073/pnas.89.1.358
    1. Richards RL, Swartz GM, Schultz C, Hayre MD, Ward GS, Ballou WR, et al. . Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A. Vaccine (1989) 7:506–12. 10.1016/0264-410X(89)90274-0
    1. Rutgers T, Gordon D, Gathoye AM, Hollingdale M, Hockmeyer W, Rosenberg M, et al. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium Falciparum. Nat Biotechnol. (1988) 6:1065–70. 10.1038/nbt0988-1065
    1. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, et al. . Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis. (1995) 171:1576–85. 10.1093/infdis/171.6.1576
    1. Ansong D, Asante KP, Vekemans J, Owusu SK, Owusu R, Brobby NA, et al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS ONE (2011) 6:e18891. 10.1371/journal.pone.0018891
    1. Owusu-Agyei S, Ansong D, Asante K, Kwarteng Owusu S, Owusu R, Wireko Brobby NA, et al. . Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE (2009) 4:e7302. 10.1371/journal.pone.0007302
    1. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. . Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. (2009) 200:337–46. 10.1086/600120
    1. Leroux-Roels G, Leroux-Roels I, Clement F, Ofori-Anyinam O, Lievens M, Jongert E, et al. . Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naive adults. Hum Vaccin Immunother (2014) 10:2211–9. 10.4161/hv.29375
    1. Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, et al. . Seven-year efficacy of RTS,S/AS01 malaria vaccine among young african children. N Engl J Med. (2016) 374:2519–29. 10.1056/NEJMoa1515257
    1. Kazmin D, Nakaya HI, Lee EK, Johnson MJ, van der Most R, van den Berg RA, et al. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. Proc Natl Acad Sci USA. (2017) 114:2425–30. 10.1073/pnas.1621489114
    1. van den Berg RA, Coccia M, Ballou WR, Kester KE, Ockenhouse CF, Vekemans J, et al. Predicting RTS,S vaccine-mediated protection from transcriptomes in a malaria-challenge clinical trial. Front Immunol. (2017) 8:557. 10.3389/fimmu.2017.00557
    1. Good MF, Pombo D, Quakyi IA, Riley EM, Houghten RA, Menon A, et al. . Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA. (1988) 85:1199–203. 10.1073/pnas.85.4.1199
    1. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. . Genetic Diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Engl J Med. (2015) 373:2025–37. 10.1056/NEJMoa1505819
    1. Zevering Y, Khamboonruang C, Good MF. Natural amino acid polymorphisms of the circumsporozoite protein of Plasmodium falciparum abrogate specific human CD4+ T cell responsiveness. Eur J Immunol. (1994) 24:1418–25. 10.1002/eji.1830240627
    1. Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. (2017) 7:46621. 10.1038/srep46621
    1. Ahmad M, Hirz M, Pichler H, Schwab H. Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol. (2014) 98:5301–17. 10.1007/s00253-014-5732-5
    1. Tiwari S, Goyal AK, Mishra N, Khatri K, Vaidya B, Mehta A, et al. . Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine. J Control Release (2009) 140:157–65. 10.1016/j.jconrel.2009.08.004
    1. Tiwari S, Goyal AK, Khatri K, Mishra N, Vyas SP. Gel core liposomes: an advanced carrier for improved vaccine delivery. J Microencapsul (2009) 26:75–82. 10.1080/02652040802170897
    1. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, et al. . Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE (2008) 3:e3116. 10.1371/journal.pone.0003116
    1. Tyagi RK, Garg NK, Jadon R, Sahu T, Katare OP, Dalai SK, et al. XElastic liposome-mediated transdermal immunisation enhanced the immunogenicity of P. falciparum surface antigen, MSP-119. Vaccine (2017) 33:4630–8. 10.1016/j.vaccine.2015.06.054
    1. Giddam AK, Reiman JM, Zaman M, Skwarczynski M, Toth I, Good MF. A semi-synthetic whole parasite vaccine designed to protect against blood stage malaria. Acta Biomater. (2016). 10.1016/j.actbio.2016.08.020

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere